HRP20190841T4 - Injektabilna formulacija - Google Patents
Injektabilna formulacija Download PDFInfo
- Publication number
- HRP20190841T4 HRP20190841T4 HRP20190841TT HRP20190841T HRP20190841T4 HR P20190841 T4 HRP20190841 T4 HR P20190841T4 HR P20190841T T HRP20190841T T HR P20190841TT HR P20190841 T HRP20190841 T HR P20190841T HR P20190841 T4 HRP20190841 T4 HR P20190841T4
- Authority
- HR
- Croatia
- Prior art keywords
- injectable preparation
- preparation according
- quinolin
- thiophen
- piperazin
- Prior art date
Links
- 239000007972 injectable composition Substances 0.000 title claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- -1 fatty acid esters Chemical class 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 239000011164 primary particle Substances 0.000 claims 3
- 239000011163 secondary particle Substances 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- QNAKJJHSWWWWKD-UHFFFAOYSA-N 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1h-quinolin-2-one;dihydrate Chemical compound O.O.C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 QNAKJJHSWWWWKD-UHFFFAOYSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229950004959 sorbitan oleate Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Injektabilni pripravak koji sadrži 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili njegovu sol, veziva za čestice, i vodu za injekcije, te veziva za čestice sadrže (i) natrijev klorid i (ii) najmanje jedan član odabran iz skupine koja se sastoji od polioksietilen sorbitan estera masnih kiselina i polietilen glikola.
2. Injektabilni pripravak prema zahtjevu 1, naznačen time što vezivo za čestice sadrži natrijev klorid i polietilen glikol.
3. Injektabilni pripravak prema zahtjevu 2, naznačen time što polietilen glikol je makrogol 400 ili makrogol 4000.
4. Injektabilni pripravak prema zahtjevu 2 ili 3, naznačen time što nadalje sadrži polioksietilen sorbitan ester masne kiseline.
5. Injektabilni pripravak prema zahtjevu 4, naznačen time što polioksietilen sorbitan ester masne kiseline je polioksietilen (20) sorbitan oleat.
6. Injektabilni pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time što sekundarne čestice nastaju agregiranjem čestica (primarnih čestica) 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-ona ili njegove soli, te sekundarne čestice imaju srednji promjer čestica (srednji promjer sekundarnih čestica) od 4 do 17 µm.
7. Injektabilni pripravak prema zahtjevu 6, naznačen time što primarne čestice 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili njegove soli imaju srednji promjer primarnih čestica od 2 do 5 µm.
8. Injektabilni pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time što ima pH od 5 do 8.
9. Injektabilni pripravak prema bilo kojem od zahtjeva 1 do 8, naznačen time što pripravak oslobađa aktivni sastojak na takav način da se njegova terapijski učinkovita koncentracija u krvi održava najmanje jedan tjedan.
10. Injektabilni pripravak prema bilo kojem od zahtjeva 1 do 9, naznačen time što je 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-on ili njegova sol dihidrat 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-ona.
11. Injektabilni pripravak prema bilo kojem od zahtjeva 1 do 10, naznačen time što je za liječenje ili prevenciju recidiva shizofrenije, bipolarnog poremećaja ili depresije.
12. Injektabilni pripravak prema bilo kojem od zahtjeva 1 do 11, naznačen time što se pripravak primjenjuje intramuskularno ili potkožno.
13. Prethodno napunjena štrcaljka koja je napunjena injektabilnim pripravkom prema bilo kojem od zahtjeva 1 do 12.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636932P | 2012-04-23 | 2012-04-23 | |
| US201361791896P | 2013-03-15 | 2013-03-15 | |
| PCT/JP2013/061950 WO2013161830A1 (ja) | 2012-04-23 | 2013-04-23 | 注射製剤 |
| EP13781458.8A EP2868318B2 (en) | 2012-04-23 | 2013-04-23 | Injectable formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20190841T1 HRP20190841T1 (hr) | 2019-07-26 |
| HRP20190841T4 true HRP20190841T4 (hr) | 2022-03-04 |
Family
ID=49483139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190841TT HRP20190841T4 (hr) | 2012-04-23 | 2019-05-07 | Injektabilna formulacija |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20150086632A1 (hr) |
| EP (1) | EP2868318B2 (hr) |
| JP (1) | JP6249944B2 (hr) |
| KR (1) | KR102168263B1 (hr) |
| CN (4) | CN104363912A (hr) |
| AR (1) | AR090775A1 (hr) |
| AU (1) | AU2013253518B2 (hr) |
| BR (1) | BR112014026398B1 (hr) |
| CA (1) | CA2871398C (hr) |
| CO (1) | CO7151499A2 (hr) |
| CY (1) | CY1123195T1 (hr) |
| DK (1) | DK2868318T4 (hr) |
| EA (1) | EA026124B1 (hr) |
| ES (1) | ES2727454T5 (hr) |
| HK (1) | HK1205678A1 (hr) |
| HR (1) | HRP20190841T4 (hr) |
| HU (1) | HUE043686T2 (hr) |
| IL (1) | IL235211A0 (hr) |
| IN (1) | IN2014DN08870A (hr) |
| JO (1) | JO3524B1 (hr) |
| LT (1) | LT2868318T (hr) |
| MX (1) | MX361722B (hr) |
| MY (1) | MY169099A (hr) |
| NZ (1) | NZ630255A (hr) |
| PH (1) | PH12014502366A1 (hr) |
| PL (1) | PL2868318T5 (hr) |
| PT (1) | PT2868318T (hr) |
| SG (2) | SG11201406775UA (hr) |
| SI (1) | SI2868318T2 (hr) |
| TW (1) | TWI641395B (hr) |
| UA (1) | UA118084C2 (hr) |
| WO (1) | WO2013161830A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| WO2017106641A1 (en) * | 2015-12-17 | 2017-06-22 | Assia Chemical Industries Ltd. | Solid state forms of brexpiprazole |
| US10501450B2 (en) | 2016-02-01 | 2019-12-10 | Hexal Ag | Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations |
| WO2017208251A1 (en) * | 2016-05-31 | 2017-12-07 | Cipla Limited | A new stable polymorph of brexpiprazole and process for preparation thereof |
| US20200093821A1 (en) * | 2016-08-16 | 2020-03-26 | Hexal Ag | Pharmaceutical Compositions of a Benzothiophene Compound |
| EP3577111A1 (en) | 2017-02-02 | 2019-12-11 | Hexal Aktiengesellschaft | Crystalline brexpiprazole |
| JPWO2021029020A1 (hr) * | 2019-08-13 | 2021-02-18 | ||
| CN117794517A (zh) | 2021-09-07 | 2024-03-29 | 四川科伦药物研究院有限公司 | 注射用布瑞哌唑长效制剂及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
| WO1998051281A1 (fr) | 1997-05-14 | 1998-11-19 | Senju Pharmaceutical Co., Ltd. | Preparations a base de suspensions aqueuses possedant d'excellentes proprietes de redispersion |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| US20030195179A1 (en) | 2000-08-25 | 2003-10-16 | Shirou Sawa | Aqueous suspension preparations |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| PL1675573T4 (pl) * | 2003-10-23 | 2016-04-29 | Otsuka Pharma Co Ltd | Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP2009508859A (ja) * | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
| TW200808375A (en) | 2006-05-12 | 2008-02-16 | Otsuka Pharma Co Ltd | Hydrogel suspension and manufacturing process thereof |
| TWI415629B (zh) * | 2006-10-26 | 2013-11-21 | Otsuka Pharma Co Ltd | 含有瑞巴匹特之水性醫藥懸浮物及其製造方法 |
| EP2170279B1 (en) | 2007-07-31 | 2017-12-27 | Otsuka Pharmaceutical Co., Ltd. | Methods for producing aripiprazole suspension and freeze-dried formulation |
| AU2009223649B2 (en) * | 2008-03-11 | 2013-08-29 | Novartis Ag | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
| AU2009316708B2 (en) * | 2008-11-19 | 2014-07-17 | Boehringer Ingelheim Animal Health USA Inc. | Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol |
| RU2535089C2 (ru) * | 2010-08-24 | 2014-12-10 | Оцука Фармасьютикал Ко., Лтд. | Суспензия и затвердевшая композиция, содержащие производное карбостирила и силиконовое масло и/или производное силиконового масла |
| KR101936968B1 (ko) * | 2010-10-18 | 2019-01-09 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 주사용 서방형 제제 |
| CN107252414B (zh) * | 2011-03-18 | 2020-11-24 | 奥克梅斯制药爱尔兰有限公司 | 包含脱水山梨糖醇酯的药物组合物 |
| JP2012232958A (ja) | 2011-05-09 | 2012-11-29 | Otsuka Pharmaceut Co Ltd | 注射製剤 |
| AU2013235526B2 (en) * | 2012-03-19 | 2017-11-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
-
2013
- 2013-04-22 AR ARP130101320A patent/AR090775A1/es not_active Application Discontinuation
- 2013-04-23 TW TW102114433A patent/TWI641395B/zh active
- 2013-04-23 JP JP2014512621A patent/JP6249944B2/ja active Active
- 2013-04-23 CN CN201380021612.2A patent/CN104363912A/zh active Pending
- 2013-04-23 US US14/395,681 patent/US20150086632A1/en not_active Abandoned
- 2013-04-23 KR KR1020147032097A patent/KR102168263B1/ko active IP Right Grant
- 2013-04-23 LT LTEP13781458.8T patent/LT2868318T/lt unknown
- 2013-04-23 AU AU2013253518A patent/AU2013253518B2/en active Active
- 2013-04-23 MX MX2014012734A patent/MX361722B/es active IP Right Grant
- 2013-04-23 JO JOP/2013/0115A patent/JO3524B1/ar active
- 2013-04-23 CN CN201911077087.1A patent/CN110638752A/zh active Pending
- 2013-04-23 MY MYPI2014703102A patent/MY169099A/en unknown
- 2013-04-23 PL PL13781458T patent/PL2868318T5/pl unknown
- 2013-04-23 EP EP13781458.8A patent/EP2868318B2/en active Active
- 2013-04-23 SG SG11201406775UA patent/SG11201406775UA/en unknown
- 2013-04-23 WO PCT/JP2013/061950 patent/WO2013161830A1/ja active Application Filing
- 2013-04-23 SG SG10201608684QA patent/SG10201608684QA/en unknown
- 2013-04-23 CA CA2871398A patent/CA2871398C/en active Active
- 2013-04-23 PT PT13781458T patent/PT2868318T/pt unknown
- 2013-04-23 HU HUE13781458A patent/HUE043686T2/hu unknown
- 2013-04-23 CN CN201710701596.1A patent/CN107536802A/zh active Pending
- 2013-04-23 UA UAA201412554A patent/UA118084C2/uk unknown
- 2013-04-23 NZ NZ630255A patent/NZ630255A/en unknown
- 2013-04-23 EA EA201491937A patent/EA026124B1/ru not_active IP Right Cessation
- 2013-04-23 IN IN8870DEN2014 patent/IN2014DN08870A/en unknown
- 2013-04-23 DK DK13781458.8T patent/DK2868318T4/da active
- 2013-04-23 BR BR112014026398-1A patent/BR112014026398B1/pt active IP Right Grant
- 2013-04-23 CN CN202010921162.4A patent/CN111888329A/zh active Pending
- 2013-04-23 ES ES13781458T patent/ES2727454T5/es active Active
- 2013-04-23 SI SI201331442T patent/SI2868318T2/sl unknown
-
2014
- 2014-10-20 IL IL235211A patent/IL235211A0/en active IP Right Grant
- 2014-10-22 PH PH12014502366A patent/PH12014502366A1/en unknown
- 2014-11-21 CO CO14255947A patent/CO7151499A2/es unknown
-
2015
- 2015-06-29 HK HK15106178.4A patent/HK1205678A1/xx unknown
-
2017
- 2017-09-12 US US15/702,361 patent/US10624889B2/en active Active
-
2019
- 2019-05-07 HR HRP20190841TT patent/HRP20190841T4/hr unknown
- 2019-06-06 CY CY20191100602T patent/CY1123195T1/el unknown
-
2020
- 2020-01-28 US US16/775,222 patent/US20200163960A1/en not_active Abandoned
-
2022
- 2022-02-11 US US17/650,822 patent/US20220305007A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190841T4 (hr) | Injektabilna formulacija | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| HRP20191366T4 (hr) | Injekcijski pripravak | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| HRP20211899T1 (hr) | Formulacija protutijela | |
| HRP20161280T1 (hr) | Farmaceutski pripravci | |
| EA033373B1 (ru) | Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему | |
| NZ730821A (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| JP2015525763A5 (hr) | ||
| BR112015012547A2 (pt) | composições de prostaciclina e métodos de sua utilização | |
| IN2014CN02592A (hr) | ||
| RU2012102247A (ru) | Инъекционные композиции, содержащие асенапин и способ лечения с их применением | |
| EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
| JP2016503398A5 (hr) | ||
| JP2012530130A5 (hr) | ||
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| BR112012003907A2 (pt) | composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
| HRP20161794T1 (hr) | Novi terapijski pristupi za liječenje neuroinflamatornih stanja | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 | |
| RU2014141615A (ru) | Новое противоопухолевое средство, включающее комбинацию трех агентов | |
| EA201791458A1 (ru) | Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта |